logo

For the Inventor, By the Inventor

La Jolla, CA, United States of America

Inhibrx, Inc.


USPTO Granted Patents = 30



Trademarks = 2

Forward Citations = 141

Loading Chart...
Loading Chart...

23 inventors (with patents filed for the assignee):

goldMedal John C Timmer (30 out of 44 patents)

silverMedal Brendan P Eckelman (30 out of 48 patents)

bronzeMedal Quinn L Deveraux (24 out of 39 patents)

4.  Kyle S Jones (14 out of 15 patents)

5.  Amir S Razai (10 out of 12 patents)

6.  Peter L Nguy (9 out of 9 patents)

7.  Abrahim Hussain (8 out of 10 patents)

8.  Katelyn M Willis (7 out of 14 patents)

9.  Grant B Guenther (7 out of 7 patents)

10.  Rajay A Pandit (5 out of 11 patents)

11.  Andrew Hollands (5 out of 7 patents)

12.  Bryan Becklund (4 out of 5 patents)

13.  William Crago (4 out of 7 patents)

14.  Angelica N Sanabria (3 out of 10 patents)

15.  Florian Sulzmaier (3 out of 4 patents)


Core Competencies:
OX40-binding Polypeptides
DR5-binding Fusion Proteins
Single Domain Antibodies
CD123-binding Polypeptides
Serpin Fusion Polypeptides
Multispecific Constructs
GITR-binding Fusion Proteins
Type III Secretion System

30 patents:

1. 12012459 - OX40-binding polypeptides and uses thereof (2024-06-18),
2. 11976126 - Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells (2024-05-07),
3. 11965017 - Serpin fusion polypeptides and methods of use thereof (2024-04-23),
4. 11945869 - PD-1 single domain antibodies and therapeutic compositions thereof (2024-04-02),
5. 11919963 - CD123-binding polypeptides and uses thereof (2024-03-05),
6. 11866507 - Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same (2024-01-09),
7. 11827691 - Serpin fusion polypeptides and methods of use thereof (2023-11-28),
8. 11566078 - PDL1-binding proteins (2023-01-31),
9. 11560428 - CD33-binding polypeptides and uses thereof (2023-01-24),
10. 11434297 - CD123-binding polypeptides and uses thereof (2022-09-06),
11. 11208485 - PD-1 single domain antibodies and therapeutic compositions thereof (2021-12-28),
12. 11117973 - Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms (2021-09-14),
13. 11117972 - Multivalent and multispecific OX40-binding fusion proteins (2021-09-14),
14. 11046752 - Serpin fusion polypeptides and methods of use thereof (2021-06-29),
15. 10844129 - Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids (2020-11-24),
Inhibrx, Inc. is a biotechnology company based in La Jolla, California, focused on developing innovative therapies for patients with serious diseases. The company specializes in the design and development of biologic therapeutics, particularly in the fields of oncology and autoimmune disorders. Inhibrx leverages advanced protein engineering and drug discovery technologies to create novel treatments that aim to improve patient outcomes and address unmet medical needs.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Inhibrx, Inc.
30 Patents

#21 in La Jolla, CA

#2,677 in California

#11,225 in US

#21,853 in the World

La Jolla, CA (US)
La Jolla, CA, United States of America

Inhibrx, Inc.

Forward Citations = 141

23 inventors:

goldMedal John C Timmer (30 out of 44 patents)

silverMedal Brendan P Eckelman (30 out of 48 patents)

bronzeMedal Quinn L Deveraux (24 out of 39 patents)

4.  Kyle S Jones (14 out of 15 patents)

5.  Amir S Razai (10 out of 12 patents)

Please report any incorrect information to [email protected]
Loading…